• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Frontiers in Reproductive Health

    Frontiers in Reproductive Health

    JournalISSN 2673-3153eISSN 2673-3153中科院 医学 4区

    年发文量

    研究主题

    论文(1029)

    排序
    1Italian Expert Discussion on the Importance of Timely Recognizing the Most Common Disruptive Symptoms Associated with Menopause at Usual Age and Premature Menopause
    Rossella E. Nappi,Angelo Cagnacci,Costantino Di Carlo,Stefano Lello, Francesca Nocera, Giovanna M. Salerno

    IntroductionMenopause is a universal physiological transition, yet its associated symptoms and long-term health implications are often underestimated. In Italy, approximately 10 million women aged 45–65 years may experience menopausal symptoms. Epidemiological data indicate that moderate-to-severe vasomotor symptoms (VMS) affect over half of menopausal women, while awareness and appropriate management remain limited, with only a small proportion receiving menopause hormone therapy, the gold standard treatment for eligible symptomatic women.Methodsa panel of Italian representatives of the most relevant scientific societies developed this narrative review informed by expert discussion. A common view was reached through a structured discussion of predefined clinical questions addressing timing of menopause counseling, most disruptive symptoms across different types of menopause, relevant risk factors, importance of symptoms detection, underserved populations and strategies to improve care pathways.ResultsEarly recognition of menopausal transition and its most disruptive symptoms which significantly impact quality of life (QoL) is of the utmost importance. Symptoms may persist for several years, with VMS lasting on average 7.4 years and genitourinary syndrome of menopause (GSM) presenting as a chronic condition. The clinical relevance of menopause is influenced by multiple biopsychosocial factors, including age, body mass index, smoking, sleep disturbances, and psychosocial stressors. Menopause at usual age and premature and treatment-induced menopause share similar symptom profiles, although severity may differ, particularly in surgical or cancer-related menopause, where symptoms and QoL impairment are often more pronounced. Evidence shows that disruptive symptoms are associated with broader health outcomes, including cardio-metabolic risk, bone health, and cognitive function. Italian experts underscore significant gaps in menopause care, particularly among women with premature menopause, chronic conditions, or low health literacy. These groups face higher risks of cardiovascular disease, osteoporosis, and reduced survival, alongside limited access to effective, evidence-based treatments.DiscussionA proactive, multidisciplinary patient-centered approach is recommended to improve menopause care pathways. Early counseling, individualized benefit-risk assessment, and integration of lifestyle interventions are essential to enhance QoL and prevent long-term complications. Strengthening education for both healthcare professionals and the general population, improving epidemiological data collection, and developing structured care pathways represent key priorities for advancing menopause management in Italy.

    2026
    引用
    AI阅读
    加入学术空间
    2IRIS: a Randomized Controlled Trial in India Comparing Efficacy and Safety of Individualized Follitropin Delta Dosing with Conventional Follitropin Alfa During First Ovarian Stimulation Cycle for in Vitro Fertilization
    Nayana Patel,Padma Rekha Jirge, Shalini Srivastava,Neena Malhotra,Sanjeeva Reddy, Vyjayanthi Srinivasan, Mirudhubashini Govindarajan, Manish Banker, Enrica Gravotta,Ali Falahati,Rita Lobo

    BackgroundWomen of Indian ethnicity are underrepresented among randomized controlled trials (RCTs) in reproductive medicine. We compared individualized follitropin delta with conventional follitropin alfa in infertile Indian women undergoing their first ovarian stimulation cycle for (IVF) or intracytoplasmic sperm injection (ICSI).MethodsIndian participants, 21–40 years, were recruited from specialist fertility clinics across India to enroll in this assessor-blinded, multicenter bridging trial. Participants were randomly assigned (1:1) to individualized follitropin delta (algorithmic dosing based on serum anti-Müllerian hormone and bodyweight) or conventional follitropin alfa (starting dose 150 IU/day) in a GnRH antagonist protocol. The primary endpoint was the ongoing pregnancy rate per initiated cycle, and treatment difference was adjusted for age stratum (<35, 35–37 and 38–40 years) using the Mantel-Haenszel method. Secondary endpoints included ovarian responses, safety, and tolerability. An exploratory post hoc multivariate logistic analysis for ongoing pregnancy was performed using treatment group, age, AMH subgroup (<15 or ≥15 pmol) and infertility history as covariates.FindingsBetween 03-Dec-2021, and 13-Dec-2023, 249 participants were screened, 215 randomized, and 213 exposed to the study drug [n = 99 follitropin delta; n = 114 follitropin alfa; modified intention-to-treat (mITT) analysis set]. Baseline characteristics were mostly similar between groups. The ongoing pregnancy rate was 22.2% (22/99) with follitropin delta vs. 14.9% (17/114) with follitropin alfa (age-adjusted difference 6.9% [95% CI −3.4–17.3]; post hoc multivariate adjusted difference 10.1%; odds ratio 1.99 [95% CI 0.95, 4.19]; p = 0.692). Participants had a mean oocyte yield ± standard deviation of 7.7 ± 5.3 in the follitropin delta group and 6.9 ± 4.2 in the follitropin alfa group. The mean total gonadotropin dose was ∼26% lower with follitropin delta (mean treatment difference −32.0 µg; p < 0.001, post-hoc analysis; mITT). The incidence of adverse events was similar between groups (34.3% vs. 29.8%), with no cases of OHSS reported.InterpretationThe IRIS trial demonstrates that individualized dosing of follitropin delta is an effective and safe strategy for ovarian stimulation in Indian women while reducing total gonadotropin dose requirements. Ongoing pregnancy rates were numerically higher with follitropin delta in both the primary analysis and the post hoc multivariate logistic regression analysis, confirming the robustness of the results.FundingFerring Pharmaceuticals A/SRegistrationClinicalTrials.gov: NCT04773353; CTRI: CTRI/2021/04/032835.

    2026
    引用
    AI阅读
    加入学术空间
    3Endometriosis Care in Germany: a Critical Narrative Review of Diagnostic Pathways, Delays and Health Services Research Gaps
    Martin Weiß, Matthias Stope, Axel Olaf Kern, Kathleen Hirsch, Sven Leonhardt, Scott Meinhardt, Laura Schladitz

    BackgroundEndometriosis is associated with heterogeneous symptoms and frequently involves a prolonged route from symptom onset to diagnosis. The term diagnostic delay is used for different intervals, however, and studies vary in their populations, diagnostic endpoints and healthcare settings. In Germany, evidence is distributed across specialist-centre studies, qualitative research, health-services and clinical guidelines.ObjectiveTo critically synthesise the available Germany-relevant evidence on diagnostic delay and the diagnostic pathway of endometriosis, with particular attention to the distinction between patient, provider and system processes, the interpretation of administrative data, and priorities for German health-services research.Review approachA focused, non-systematic search and source-identification approach was used. The literature was identified through focused searches of PubMed, publicly accessible publisher and registry pages, German health-services sources including the Versorgungsatlas, national and international guidelines, and backward and forward citation searching. German primary studies were prioritised; international reviews and selected European guidance were used for conceptual context. Sources were selected for direct relevance to diagnostic intervals, healthcare contacts, referrals, diagnostic attribution, access or patient experience. No complete multi-database export, duplicate screening or formal systematic-review workflow was undertaken.SynthesisGerman evidence indicates that the pathway to diagnosis can extend over several years, but the reported estimates are not directly interchangeable. A mixed Austria–Germany tertiary-centre study reported a median symptom-to-diagnosis interval of 10.4 years, while a German EndoCost analysis reported a mean total interval of 7.0 years, with mean patient and physician intervals of 2.8 and 4.2 years, respectively. A qualitative German study describes the importance of being heard, symptom recognition and communication in healthcare encounters. Nationwide claims and Versorgungsatlas analyses describe documented diagnosis patterns and regional variation, but cannot measure symptom onset or the unrecorded period before diagnosis.ConclusionsThe available evidence supports understanding diagnostic delay as a cumulative, cross-sector pathway problem rather than as one nationally representative number or one isolated clinical failure. Germany needs standardised interval definitions, prospective longitudinal data, linkage of patient-reported information with routine-care trajectories, and implementation research on referral and specialist access. The conclusions are limited by the non-systematic search and by the selection and measurement limitations of the underlying studies.

    2026
    引用
    AI阅读
    加入学术空间
    4Individualized Treatment Effect of GnRH Antagonist Versus Depot GnRH-a Long Protocol on Cumulative Live Birth: a Causal Forest Approach
    Caihui Ma, Yurong Chen,Jianzhi Ren, Jie Geng,Haixiao Chen,Luxiang Pan,Xuhong Na,Ling Ouyang,Jiali Cai,Xiaoming Jiang

    PurposeTo balance the benefits and risks of different controlled ovarian stimulation (COS) protocols, we evaluated the individualized treatment effect (ITE) of the GnRH antagonist protocol versus the follicular phase depot GnRH-a long protocol, corresponding to the cumulative live birth rate (CLBR).MethodsA retrospective cohort study included 17,571 IVF/ICSI cycles from January 2016 to December 2022. Propensity score matching was performed and a causal forest model was trained to estimate the ITE. SHAP analysis quantified feature contributions, and generalized additive models were used to visualize feature effects.ResultsIn this exploratory analysis, the depot GnRH-a long protocol demonstrated superior treatment effects compared to the antagonist protocol (ITE range: −0.199 to −0.034). However, higher ITE values correlated with increased OHSS incidence in agonist cycles. An exploratory counterfactual analysis suggested that reallocating patients with ITE > −0.115 to the antagonist protocol would reduce CLBR by 6.08 percentage points (64.30% vs. 58.23%) but decrease OHSS rate by 0.31 percentage points (1.61% vs. 1.30%). In the exploratory SHAP analysis, basal estradiol (E2) appeared as the strongest modifier: the antagonist protocol tended to be favored in patients with low basal E2, high BMI, older age, or extreme AMH levels.ConclusionsAlthough confirmation in prospective randomized studies is required, the follicular phase depot GnRH-a long protocol may achieve higher CLBR than the GnRH antagonist protocol and was accompanied by elevated OHSS risk. In this exploratory analysis, the ITE estimates suggested a potential trade-off between CLBR and OHSS risk. Basal E2 may be considered as an additional marker when selecting a controlled ovarian stimulation protocol.

    2026
    引用
    AI阅读
    加入学术空间
    5Expert Consensus on Ovarian Stimulation Strategies for Assisted Reproductive Technology: Insights from the ASEAN Region
    Murizah Mohd Zain,Budsaba Wiriyasirivaj,Le Hoang, Jessie W. L. Phoon, Lei Jun Lim, Maria Victoria Romualdez-Tan,Rudie Frederick Mendiola, Teraporn Vutyavanich,Zhongwei Huang,Tuong Manh Ho

    BackgroundInfertility remains a major global public health issue, affecting an estimated 17.5% of couples of reproductive age in their lifetime. Fertility rates in ASEAN countries have declined below replacement thresholds, highlighting the urgent need to enhance assisted reproductive technology (ART) strategies. Controlled ovarian stimulation is central to optimising ART outcomes, yet guidance tailored to ASEAN population is limited.MethodsA comprehensive literature review (January 2015 to April 2025) informed the development of thirty statements, referencing the European Society of Human Reproduction and Embryology (ESHRE) Guideline on Ovarian Stimulation for in-vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) 2025. A modified Delphi methodology and GRADE-ADOLOPMENT framework were employed to ensure evidence-based, context-sensitive recommendations. Statements deemed irrelevant to this consensus discussion were excluded. Consensus was defined as ≥70% expert agreement.ResultsOf 30 draft statements, consensus was achieved on 28 final statements after three Delphi rounds. Gonadotrophin-releasing hormone (GnRH) antagonist protocols were considered safe and preferred in predicted normal and high responders with comparable efficacy. In freeze-all cycles, progestin protocol was considered probably equivalent to GnRH analogues for pituitary suppression. Recombinant follicle-stimulating hormone (rFSH) and highly-purified human menopausal gonadotrophin (HP-hMG) were equally recommended; however, in predicted high responders, HP-hMG was noted to potentially reduce the risk of ovarian hyperstimulation syndrome (OHSS). Mixed stimulation protocols combining rFSH and HP-hMG from the start of stimulation are favoured over mid-follicular phase combinations for predicted normal and low responders. Follitropin delta and alpha/beta were considered probably equivalent, with algorithm-guided follitropin delta preferred when OHSS risk is a concern. Adjunctive letrozole or clomiphene was generally not recommended. Mid-cycle dose adjustments may be used pragmatically to reduce the risk of cycle cancellation or OHSS, and recombinant luteinising hormone (rLH) supplementation may benefit selected subgroups (e.g., advanced age or low responders), although evidence remains heterogeneous.ConclusionThis consensus provides evidence-informed ovarian stimulation strategies tailored to different patient profiles, emphasising safety, efficacy, and personalisation to optimise IVF/ICSI outcomes. Where evidence is limited, statements reflect expert consensus and should be applied as conditional guidance. It balances global best practices with regional realities to support effective, safer, and personalised ART in ASEAN.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1029 篇论文

    高被引作者

    作者引用发文
    Pallav Sengupta1841
    Ajayi Ayodeji F1841
    Gulfam Ahmad1841
    Moses A. Hamed1841
    Sulagna Dutta1841
    Roland Eghoghosoa Akhigbe1841
    Saiqa Mullick16912
    Dolan Siobhan M1632
    William W. Hay1591
    Wylie Burke1591

    高产作者

    作者引用发文
    Saiqa Mullick16912
    Linda-Gail Bekker849
    Kinuthia John859
    Renee Heffron477
    Ana Katherine Da Silveira Goncalves De Oliveira1137
    Grace C. John-Stewart747
    Jared Baeten986
    Ayane Cristine Alves Sarmento1136
    Elizabeth Bukusi986
    Jose Eleuterio1096

    相关期刊

    Ciencias de la conducta : revista del Centro Caribeno de Estudios Post-Graduados
    Evidence Based Care Journal
    Cin-computers Informatics Nursing
    The Journal of Special Children Education
    Middle East Journal of Nursing
    Iranian Journal of Medical Education
    Health Service Management Review
    Epidemiology Bulletin
    BELITUNG NURSING JOURNAL
    Pielegniarstwo XXI Wieku-Nursing in the 21 Century